US4582717A - Process for production of vaginal tampons containing pharmaceutical active compound - Google Patents

Process for production of vaginal tampons containing pharmaceutical active compound Download PDF

Info

Publication number
US4582717A
US4582717A US06/634,941 US63494184A US4582717A US 4582717 A US4582717 A US 4582717A US 63494184 A US63494184 A US 63494184A US 4582717 A US4582717 A US 4582717A
Authority
US
United States
Prior art keywords
sub
tampon
clotrimazole
chain length
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US06/634,941
Inventor
Miklos von Bittera
Karl H. Buchel
Manfred Plempel
Erik Regel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of US4582717A publication Critical patent/US4582717A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/202—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with halogen atoms, e.g. triclosan, povidone-iodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/408—Virucides, spermicides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S604/00—Surgery
    • Y10S604/904—Tampons

Definitions

  • the present invention relates to novel formulations of the known antimycotic azole derivatives, which exhibit a higher release of the active compounds and thereby make short-term therapy possible.
  • Formulations of antimycotic azole derivatives, which form tampons, for the treatment of vaginal infections with fungi have already been disclosed [Current Therapeutic Research, Vol. 23, No.6, June 1978, 661-665]. With these formulations, 14 to 3 days therapy time are necessary to complete vaginal clean-up. This is attributable, inter alia, to the fact that the active compound contained in the known tampon formulations is only partially soluble in aqueous media. However, it is desirable to have tampons available with which briefer therapy is possible.
  • a higher release of the active compounds in the aqueous medium is required.
  • the known formulations are only suitable to limited extent for this purpose, since only a small proportion of the active compound available dissolves in the volume of liquid at the site of infection.
  • the tampons are coated with a carrier material which consists of a base which only melts above body temperature and in which the active compound is present in the form of coarse crystals and is unchanged at body temperature.
  • Active compounds which can be formulated in this manner are all derivatives having antimycotic activity, in particular imidazole and triazole derivatives. They are present in the tampons according to the invention in amounts of 50-300 mg, preferably of 100-200 mg.
  • the carrier material for impregnation must comply with the following requirements:
  • Suppository bases with spreading agent and solubiliser with spreading agent and solubiliser.
  • Solid spreading agents melting at body temperature.
  • Solid spreading agents melting at body temperature with spreading oils and solubiliser.
  • Solid solvents melting at room temperature for example ethylene carbonate.
  • suppository bases are suitable as carrier material for the agents according to the invention:
  • the following compounds are, for example, suitable as solid spreading agents melting at body temperature: myristyl lactate, cetyl lactate, myristyl myristate and similar compounds.
  • Spreading agents are understood to include oily fluids which distribute particularly well on the skin [R. Keymer, Pharm. Ind. 32, 577-581 (1970)].
  • the following compounds are particularly suitable as spreading agents or oils:
  • Silicone oils of various viscosity are silicone oils of various viscosity.
  • Fatty acid esters such as ethyl stearate, di-n-butyl adipate, hexyl laurate, dipropylene glycol pelargonate, esters of a branched fatty acid of moderate chain length with saturated fatty alcohols C 16 -C 18 , isopropyl myristate, isopropyl palmitate, caprylic/capric acid esters of separated fatty alcohols of chain length C 12 -C 18 , isopropyl stearate, oleyl oleate, decyl oleate, ethyl oleate, wax-like fatty acid esters, such as artificial duck preen gland fat, dibutyl phthalate, diisopropyl adipate, ester mixtures related to the latter and the like.
  • esters such as ethyl stearate, di-n-butyl adipate, hexyl laurate, dipropylene glycol
  • Triglycerides such as caprylic/capric acid triglyceride, mixtures of triglycerides with plant fatty acids of chain length C 8 -C 12 or other specially selected natural fatty acids, partial glyceride mixtures of saturated or unsaturated fatty acids, possibly also containing hydroxyl groups, monoglycerides of C 8 /C 10 fatty acids and the like.
  • Fatty alcohols such as isotridecyl alcohol, cetylstearyl alcohol and oleyl alcohol.
  • Fatty acids such as, for example, oleic acid.
  • Glycerol high viscosity paraffin and low viscosity paraffin.
  • agents according to the invention are suitable as emulsifiers:
  • auxiliaries and/or formulation base auxiliaries can be used in manufacturing the agents according to the invention:
  • Surfactant (contains emulsifiers and wetting agent), for example
  • anion-active such as Na lauryl sulphate, fatty alcohol ether sulphates, mono/dialkylpolyglycol ether orthophosphates-monoethanolamine salt;
  • cation-active such as cetyltrimethylammonium chloride
  • ampholytic such as di-Na N-lauryl- ⁇ -ininodipropionate or lecithin;
  • non-ionic for example polyoxyethylated castor oil, polyoxyethylated sorbitan monooleate, sorbitan monostearate or cetyl alcohol.
  • ethylene carbonate and polyethylene glycols having moderate molecular weights are suitable as solid solvents only melting at body temperature.
  • 2-Octyldodecanol 2-Octyldodecanol, benzyl alcohol, ethyl lactate, propylene glycol, di- and tripropylene glycol and the like.
  • the tampons according to the invention are manufactured in the following manner:
  • the basic material consisting of active compound and formulating auxiliaries, melted and cooled down to 40° C., was weighed in portions of 2.0 g into 3 cm high glass vessels having a diameter of 1.5 cm. The pre-cooled tampons were pressed into the material so that they were surrounded at the level of the glass rim by the solidifying material.
  • the glass vessels with the tampons were wrapped in aluminium foil for protection from moisture and placed in a refrigerator to complete solidification.
  • the coated tampons could subsequently be easily removed from the glass vessels.
  • the basic material consisting of active compound and formulating auxiliaries, melted and cooled down to 40° C., was injected, using a pre-warmed 2 ml injection syringe, the capacity of which had previously been calibrated to 2.0 g by injection into tared tampons, from the point into pre-warmed tampons which were still wrapped in protective foil.
  • the impregnation material must comply with the following requirements: sufficient consistency up to 32° C., homogeneity, sufficient ability to dissolve the active compound, sufficient ability to release it, suitable melting characteristics and good in vitro effectiveness.
  • each of the different vaginal tampons impregnated in each case with 100 or 200 mg of the active compounds to be tested, were placed in 10 cm high glass beakers which were filled with Kimmig nutrient agar to a height of 5 cm. Before introducing the tampons, holes of the diameter of the tampons were bored in the centre of the agar dishes using sterile cork borers.
  • the surfaces of the agar in the dishes were then homogeneously inoculated with suspensions of organisms of C. albicans or T. glabrata.
  • the density of organisms was 10 4 cells per cm 2 .
  • test dishes thus prepared were incubated at 37° C. for 48 hours in an incubation chamber.

Abstract

The invention relates to a process for production of tampons containing novel formulations of antimycotic azole derivatives which provide a higher release of active compounds and make short-term therapy possible. The tampon formulations of the invention contain active antimycotic azole derivatives in impregnated form, only melting at body temperature, or dissolved form, such as, for example, in suppository bases or their combinations with emulsifiers and/or spreading agents and/or solubilisers.

Description

This is a division of application Ser. No. 460,083 filed Jan. 21, 1983 now abandoned.
The present invention relates to novel formulations of the known antimycotic azole derivatives, which exhibit a higher release of the active compounds and thereby make short-term therapy possible.
Formulations of antimycotic azole derivatives, which form tampons, for the treatment of vaginal infections with fungi have already been disclosed [Current Therapeutic Research, Vol. 23, No.6, June 1978, 661-665]. With these formulations, 14 to 3 days therapy time are necessary to complete vaginal clean-up. This is attributable, inter alia, to the fact that the active compound contained in the known tampon formulations is only partially soluble in aqueous media. However, it is desirable to have tampons available with which briefer therapy is possible.
In order to achieve a shortening of the duration of therapy for vaginal mycoses, particularly for eliminating the organisms, and in order to achieve a reliable mycological clean-up, a higher release of the active compounds in the aqueous medium is required. The known formulations are only suitable to limited extent for this purpose, since only a small proportion of the active compound available dissolves in the volume of liquid at the site of infection. The tampons are coated with a carrier material which consists of a base which only melts above body temperature and in which the active compound is present in the form of coarse crystals and is unchanged at body temperature.
In tampons coated in this manner, the active compound is slowly and gradually dissolved out and there exists the danger that the released active compound is absorbed again in the swelling tampons. For this reason, in vitro release results exhibit an effectiveness which fluctuates very widely and differs locally on the tampon. If it is now intended to achieve a shortening of the duration of therapy, for example to one day with administration three times, by or without further increase in the concentration of active compound, care must be taken that the bioavailability of the active compound is optimal.
It has not been found that those tampon formulations of antimycotic azole derivatives which contain the active compound in an impregnated form, only melting at body temperature, or dissolved form, such as, for example, in suppository bases or their combinations with emulsifiers and/or spreading agents and/or solubilisers, release the active compound to a greater extent and thereby make possible a shortening of the duration of therapy to 1 day. This effect of the higher release of active compound can extend up to a power of ten.
Active compounds which can be formulated in this manner are all derivatives having antimycotic activity, in particular imidazole and triazole derivatives. They are present in the tampons according to the invention in amounts of 50-300 mg, preferably of 100-200 mg.
The compounds of the formulae below may be mentioned as examples:
______________________________________                                    
     ##STR1##                Chlortriamzole                               
II                                                                        
     ##STR2##                Bifonazole                                   
III                                                                       
     ##STR3##                Lombazole                                    
______________________________________
Numerous other azole derivatives having antimycotic activity are disclosed in DE-OS (German Published Specification) No. 2,430,039. They can equally serve as active compounds in the agents according to the invention.
The carrier material for impregnation must comply with the following requirements:
Sufficient consistency at room temperature, homogeneity, sufficient ability to dissolve the active compound, sufficient ability to release it, suitable melting characteristics and uniform in vitro effectiveness.
The following possible combinations are suitable for impregnation:
Suppository bases with emulsifier.
Suppository bases with emulsifier+lactic acid.
Suppository bases with solubilisers.
Suppository bases with spreading agents.
Suppository bases with spreading agent and solubiliser.
Solid spreading agents melting at body temperature.
Solid spreading agents melting at body temperature with spreading oils.
Solid spreading agents melting at body temperature with spreading oils and solubiliser.
Solid solvents melting at room temperature, for example ethylene carbonate.
Solid solvents melting at body temperature with additional solubilisers.
The following suppository bases are suitable as carrier material for the agents according to the invention:
Mixtures of triglycerides of natural saturated fatty acids of chain length C10 -C18, triglycerides of mixtures of natural saturated plant fatty acids of chain length C10 -C18, glycerol esters of mixtures of plant saturated fatty acids, lauric acid predominating. Suppository bases having a very low hydroxyl number. Bases free of hydroxyl groups. The abovementioned bases with emulsifier, for example non-ionic emulsifiers, such as saturated C16 -C18 fatty alcohol etherified with 25 mol of ethylene oxide etc.
Mixtures of mono-, di- and triglycerides of saturated natural fatty acids of chain length C12 -C18, with or without emulsifiers.
Mixtures of mono-, di- and triglycerides, fatty alcohols, wax esters, etc.
For the agents according to the invention, the following compounds are, for example, suitable as solid spreading agents melting at body temperature: myristyl lactate, cetyl lactate, myristyl myristate and similar compounds.
Spreading agents are understood to include oily fluids which distribute particularly well on the skin [R. Keymer, Pharm. Ind. 32, 577-581 (1970)].
For the agents according to the invention, the following compounds are particularly suitable as spreading agents or oils:
Silicone oils of various viscosity.
Fatty acid esters, such as ethyl stearate, di-n-butyl adipate, hexyl laurate, dipropylene glycol pelargonate, esters of a branched fatty acid of moderate chain length with saturated fatty alcohols C16 -C18, isopropyl myristate, isopropyl palmitate, caprylic/capric acid esters of separated fatty alcohols of chain length C12 -C18, isopropyl stearate, oleyl oleate, decyl oleate, ethyl oleate, wax-like fatty acid esters, such as artificial duck preen gland fat, dibutyl phthalate, diisopropyl adipate, ester mixtures related to the latter and the like.
Triglycerides, such as caprylic/capric acid triglyceride, mixtures of triglycerides with plant fatty acids of chain length C8 -C12 or other specially selected natural fatty acids, partial glyceride mixtures of saturated or unsaturated fatty acids, possibly also containing hydroxyl groups, monoglycerides of C8 /C10 fatty acids and the like.
Fatty alcohols, such as isotridecyl alcohol, cetylstearyl alcohol and oleyl alcohol.
Fatty acids, such as, for example, oleic acid.
The following are particularly well suited spreading oils: isopropyl myristate, isopropyl palmitate, caprylic/capric acid esters of saturated fatty alcohols of chain length C12 -C18, wax-like fatty acid esters such as artificial duck preen gland fat, silicone oils and isopropyl myristate/isopropyl stearate/isopropyl palmitate mixture.
Glycerol, high viscosity paraffin and low viscosity paraffin.
For the agents according to the invention, the following agents are suitable as emulsifiers:
Colloidal-disperse mixture of cetylstearyl alcohol and sodium cetylstearyl sulphate, polyethylene stearate, cetylstearyl alcohol with about 12 mol of ethylene oxide, cetylstearyl alcohol with about 30 mol of ethylene oxide, fatty alcohol C16 -C18 etherified with 25 mol of ethylene oxide, sorbitan and glycerol fatty acid esters, ethoxylated castor oil and cetylstearyl alcohol with addition of non-ionic emulsifier.
The following other auxiliaries and/or formulation base auxiliaries can be used in manufacturing the agents according to the invention:
Surfactant (contains emulsifiers and wetting agent), for example
1. anion-active, such as Na lauryl sulphate, fatty alcohol ether sulphates, mono/dialkylpolyglycol ether orthophosphates-monoethanolamine salt;
2. cation-active, such as cetyltrimethylammonium chloride;
3. ampholytic, such as di-Na N-lauryl-β-ininodipropionate or lecithin;
4. non-ionic, for example polyoxyethylated castor oil, polyoxyethylated sorbitan monooleate, sorbitan monostearate or cetyl alcohol. Glycerol monostearate, polyoxyethylene stearate, alkylphenol polyglycol ethers and similar compounds.
For the agents according to the invention, ethylene carbonate and polyethylene glycols having moderate molecular weights are suitable as solid solvents only melting at body temperature.
The following compounds can be employed as solubilisers:
2-Octyldodecanol, benzyl alcohol, ethyl lactate, propylene glycol, di- and tripropylene glycol and the like.
All qualities of commercially available, specially treated, compressed cotton can be used as the tampon.
The tampons according to the invention are manufactured in the following manner:
(a) Coating
The basic material consisting of active compound and formulating auxiliaries, melted and cooled down to 40° C., was weighed in portions of 2.0 g into 3 cm high glass vessels having a diameter of 1.5 cm. The pre-cooled tampons were pressed into the material so that they were surrounded at the level of the glass rim by the solidifying material.
The glass vessels with the tampons were wrapped in aluminium foil for protection from moisture and placed in a refrigerator to complete solidification. The coated tampons could subsequently be easily removed from the glass vessels.
(b) Impregnation
The basic material consisting of active compound and formulating auxiliaries, melted and cooled down to 40° C., was injected, using a pre-warmed 2 ml injection syringe, the capacity of which had previously been calibrated to 2.0 g by injection into tared tampons, from the point into pre-warmed tampons which were still wrapped in protective foil.
In order to prevent the basic material solidifying too rapidly, which would make uniform impregnation difficult, the impregnated tampons were placed with the point at the bottom in pre-warmed vessels and thus cooled down slowly.
The process described according to (b) makes possible on the large-scale a rapid, uncomplicated and more exact manufacture. The tampons impregnated by this process, compared to tampons coated according to (a), show a more uniform vitro release of active compound and thus also exhibit a better therapeutic effectiveness.
The impregnation material must comply with the following requirements: sufficient consistency up to 32° C., homogeneity, sufficient ability to dissolve the active compound, sufficient ability to release it, suitable melting characteristics and good in vitro effectiveness.
PREPARATION EXAMPLES Example 1 
______________________________________                                    
Chlortrimazole (coated)                                                   
                      200    mg/tampon                                    
Mixture of mono-, di- and                                                 
                      1,450  mg                                           
triglycerides of saturated                                                
natural fatty acids of chain                                              
length C.sub.12 -C.sub.18                                                 
Cetylstearyl alcohol with non-                                            
                      150    mg                                           
ionic emulsifier                                                          
Lactic acid           200    mg                                           
______________________________________
Example 2 
______________________________________                                    
Clotrimazole (coated)                                                     
                     200    mg/tampon                                     
Mixture of mono-, di- and                                                 
                     1,600  mg                                            
triglycerides of saturated                                                
natural fatty acids of chain                                              
length C.sub.12 -C.sub.18                                                 
Benzyl alcohol       200    mg                                            
______________________________________
Example 3 
______________________________________                                    
Clotrimazole (coated)                                                     
                     200    mg/tampon                                     
Mixture of mono-, di- and                                                 
                     1,650  mg                                            
triglycerides of saturated                                                
fatty acids of chain                                                      
length C.sub.12 -C.sub.18                                                 
Benzyl alcohol       150    mg                                            
______________________________________
The following Examples 4-43 deal with impregnated formulations.
Example 4 
______________________________________                                    
Clotrimazole         200    mg/tampon                                     
Triglyceride mixture of                                                   
                     800    mg                                            
natural saturated fatty acids                                             
of chain length C.sub.10 -C.sub.18                                        
Benzyl alcohol       200    mg                                            
Myristyl myristate   800    mg                                            
______________________________________
Example 5 
______________________________________                                    
Clotrimazole         200    mg/tampon                                     
Mixture of mono-, di- and                                                 
                     800    mg                                            
triglycerides of saturated                                                
fatty acids of chain                                                      
length C.sub.12 -C.sub.18                                                 
Ethyl lactate        200    mg                                            
Benzyl alcohol       100    mg                                            
Myristyl myristate   700    mg                                            
______________________________________
Example 6 
______________________________________                                    
Clotrimazole        200    mg/tampon                                      
Benzyl alcohol      80     mg                                             
Myristyl lactate    860    mg                                             
Myristyl myristate  860    mg                                             
______________________________________
Example 7 
______________________________________                                    
Clotrimazole          200    mg/tampon                                    
Mixture of mono-, di- and                                                 
                      800    mg                                           
triglycerides of saturated fatty                                          
acids of chain length C.sub.12 -C.sub.18                                  
Ethyl lactate         200    mg                                           
Myristyl myristate    800    mg                                           
______________________________________
Example 8 
______________________________________                                    
Clotrimazole         200    mg/tampon                                     
Mixture of mono-, di- and                                                 
                     800    mg                                            
triglycerides of saturated                                                
fatty acids of chain                                                      
length C.sub.12 -C.sub.18                                                 
Ethyl lactate        200    mg                                            
Myristyl lactate     800    mg                                            
______________________________________
Example 9 
______________________________________                                    
Clotrimazole          200    mg/tampon                                    
Triglyceride mixture of natural                                           
                      800    mg                                           
saturated fatty acids of                                                  
chain length C.sub.10 -C.sub.18                                           
Ethyl lactate         200    mg                                           
Benzyl alcohol        100    mg                                           
Myristyl myristate    700    mg                                           
______________________________________
Example 10 
______________________________________                                    
Clotrimazole         200    mg/tampon                                     
Mixture of mono-, di- and                                                 
                     1,000  mg                                            
triglycerides of saturated                                                
fatty acids of chain length                                               
C.sub.12 -C.sub.18                                                        
Benzyl alcohol       100    mg                                            
Isopropyl myristate  100    mg                                            
Myristate lactate    400    mg                                            
______________________________________
Example 11 
______________________________________                                    
Clotrimazole         200    mg/tampon                                     
Mixture of mono-, di- and                                                 
                     600    mg                                            
triglycerides of saturated                                                
fatty acids of chain length                                               
C.sub.12 -C.sub.18                                                        
Benzyl alcohol       100    mg                                            
Hexyl laurate        300    mg                                            
Myristyl myristate   800    mg                                            
______________________________________
Example 12 
______________________________________                                    
Clotrimazole          200    mg/tampon                                    
Mixture of mono-, di- and                                                 
                      1,600  mg                                           
triglycerides of saturated fatty                                          
acids of chain length C.sub.12 -C.sub.18                                  
Ethyl lactate         200    mg                                           
______________________________________
Example 13 
______________________________________                                    
Clotrimazole        200    mg/tampon                                      
Benzyl alcohol      100    mg                                             
Hexyl laurate       300    mg                                             
Myristyl myristate  1,400  mg                                             
______________________________________
Example 14 
______________________________________                                    
Clotrimazole        200    mg/tampon                                      
Ethylene carbonate  1,800  mg                                             
______________________________________
Example 15 
______________________________________                                    
Clotrimazole        200    mg/tampon                                      
Benzyl alcohol      100    mg                                             
Ethylene carbonate  1,700  mg                                             
______________________________________
Example 16 
______________________________________                                    
Clotrimazole        200    mg/tampon                                      
Ethylene carbonate  1,700  mg                                             
2-Octyldodecanol    100    mg                                             
______________________________________
Example 17 
______________________________________                                    
Clotrimazole         100    mg/tampon                                     
Mixture of mono-, di- and                                                 
                     844.6  mg                                            
triglycerides of chain                                                    
length C.sub.12 -C.sub.18                                                 
Ethyl lactate        211.0  mg                                            
Benzyl alcohol       105.4  mg                                            
Myristyl myristate   739.0  mg                                            
______________________________________
Example 18 
______________________________________                                    
Clotrimazole         100    mg/tampon                                     
Triglyceride mixture of                                                   
                     844.6  mg                                            
natural saturated fatty acids                                             
of chain length C.sub.10 -C.sub.18                                        
Ethyl lactate        211.0  mg                                            
Benzyl alcohol       105.4  mg                                            
Myristyl myristate   739.0  mg                                            
______________________________________
Example 19 
______________________________________                                    
Clotrimazole        100     mg/tampon                                     
Mixture of mono-, di- and                                                 
                    1,055.2 mg                                            
triglycerides of chain                                                    
length C.sub.12 -C.sub.18                                                 
Ethyl lactate       211.0   mg                                            
Benzyl alcohol      105.4   mg                                            
Myristyl lactate    423.0   mg                                            
Isopropyl myristate 105.4   mg                                            
______________________________________
Example 20 
______________________________________                                    
Clotrimazole         100    mg/tampon                                     
Mixture of mono-, di- and                                                 
                     633.4  mg                                            
triglycerides of saturated                                                
fatty acids of chain length                                               
C.sub.12 -C.sub.18                                                        
Ethyl lactate        211.0  mg                                            
Benzyl alcohol       105.4  mg                                            
Myristyl myristate   633.4  mg                                            
Hexyl laurate        316.8  mg                                            
______________________________________
Example 21 
______________________________________                                    
Clotrimazole        100    mg/tampon                                      
Benzyl alcohol      105    mg                                             
Ethylene carbonate  1,795  mg                                             
______________________________________
Example 22 
______________________________________                                    
Clotrimazole         100    mg/tampon                                     
Polyglycol with a molecular                                               
                     450    mg                                            
weight of 1,000                                                           
Polyglycol with a molecular                                               
                     1,350  mg                                            
weight of 1,500                                                           
Benzyl alcohol       100    mg                                            
______________________________________
Example 23 
______________________________________                                    
Clotrimazole         100    mg/tampon                                     
Mixture of mono-, di- and                                                 
                     900    mg                                            
triglycerides of saturated                                                
fatty acids of chain length                                               
C.sub.12 -C.sub.18                                                        
Ethyl lactate        200    mg                                            
Benzyl alcohol       100    mg                                            
Myristyl myristate   700    mg                                            
______________________________________
Example 24 
______________________________________                                    
Clotrimazole          100    mg/tampon                                    
Triglyceride mixture of natural                                           
                      800    mg                                           
saturated fatty acids of chain                                            
length C.sub.10 -C.sub.18 with                                            
addition of 2% of a non-ionic                                             
emulsifier                                                                
Ethyl lactate         300    mg                                           
Benzyl alcohol        100    mg                                           
Myristyl myristate    700    mg                                           
______________________________________
Example 25 
______________________________________                                    
Clotrimazole          100    mg/tampon                                    
Triglyceride mixture of natural                                           
                      800    mg                                           
saturated fatty acids of chain                                            
length C.sub.10 -C.sub.18                                                 
Ethyl lactate         400    mg                                           
Myristyl myristate    700    mg                                           
______________________________________
Example 26 
______________________________________                                    
Clotrimazole         100    mg/tampon                                     
Triglycerides of saturated                                                
                     500    mg                                            
fatty acids of chain length                                               
C.sub.12 -C.sub.18                                                        
Ethyl lactate        100    mg                                            
Isopropyl myristate  200    mg                                            
Myristyl lactate     400    mg                                            
Myristyl myristate   500    mg                                            
______________________________________
Example 27 
______________________________________                                    
Clotrimazole         100    mg/tampon                                     
Triglycerides of saturated                                                
                     800    mg                                            
fatty acids of chain length                                               
C.sub.12 -C.sub.18                                                        
Ethyl lactate        400    mg                                            
Benzyl alcohol       100    mg                                            
Isopropyl myristate  300    mg                                            
Myristyl lactate     300    mg                                            
______________________________________
Example 28 
______________________________________                                    
Clotrimazole         100    mg/tampon                                     
Triglycerides of saturated                                                
                     900    mg                                            
fatty acids of chain length                                               
C.sub.12 -C.sub.18                                                        
Ethyl lactate        400    mg                                            
Isopropyl myristate  300    mg                                            
Myristyl lactate     300    mg                                            
______________________________________
Example 29 
______________________________________                                    
Clotrimazole         100    mg/tampon                                     
Triglycerides of saturated                                                
                     500    mg                                            
fatty acids of chain length                                               
C.sub.12 -C.sub.18                                                        
Ethyl acetate        200    mg                                            
Benzyl alcohol       100    mg                                            
Hexyl laurate        200    mg                                            
Myristyl lactate     400    mg                                            
Myristyl myristate   500    mg                                            
______________________________________
Example 30 
______________________________________                                    
Clotrimazole         100    mg/tampon                                     
Triglycerides of saturated                                                
                     900    mg                                            
fatty acids of chain length                                               
C.sub.12 -C.sub.18                                                        
Ethyl lactate        200    mg                                            
Benzyl alcohol       100    mg                                            
Hexyl laurate        300    mg                                            
Myristyl lactate     400    mg                                            
______________________________________
Example 31 
______________________________________                                    
Clotrimazole         100    mg/tampon                                     
Triglycerides of saturated                                                
                     900    mg                                            
fatty acids of chain length                                               
C.sub.12 -C.sub.18                                                        
Ethyl lactate        400    mg                                            
Hexyl laurate        300    mg                                            
Myristyl lactate     300    mg                                            
______________________________________
Example 32 
______________________________________                                    
Clotrimazole         100    mg/tampon                                     
Triglycerides of saturated                                                
                     650    mg                                            
fatty acids of chain length                                               
C.sub.12 -C.sub.18                                                        
Ethyl lactate        220    mg                                            
Benzyl alcohol       110    mg                                            
Hexyl laurate        320    mg                                            
Myristyl myristate   600    mg                                            
______________________________________
Example 33 
______________________________________                                    
Clotrimazole          100    mg/tampon                                    
Triglycerides of saturated                                                
                      800    mg                                           
fatty acids of chain length                                               
C.sub.12 -C.sub.18                                                        
Triglyceride mixture of natural                                           
                      800    mg                                           
saturated fatty acids of chain                                            
length C.sub.10 -C.sub.18 with                                            
addition of 2% of non-ionic                                               
emulsifier                                                                
Ethyl lactate         300    mg                                           
______________________________________
Example 34 
______________________________________                                    
Clotrimazole        100    mg/tampon                                      
Polyglycol molecular                                                      
                    350    mg                                             
weight 1,000                                                              
Polyglycol molecular                                                      
                    1,050  mg                                             
weight 1,500                                                              
Ethyl lactate       500    mg                                             
______________________________________
Example 35 
______________________________________                                    
Clotrimazole        100    mg/tampon                                      
Polyglycol molecular                                                      
                    400    mg                                             
weight 1,000                                                              
Polyglycol molecular                                                      
                    1,100  mg                                             
weight 1,500                                                              
Ethyl lactate       200    mg                                             
Benzyl alcohol      100    mg                                             
______________________________________
Example 36 
______________________________________                                    
Clotrimazole          100    mg/tampon                                    
Polyglycol molecular  360    mg                                           
weight 1,000                                                              
Polyglycol molecular  1,140  mg                                           
weight 1,500                                                              
Solubiliser of fatty acid                                                 
                      400    mg                                           
glycerol polyglycol esters                                                
and fatty acid polyglycol esters                                          
obtained by reaction of hydro-                                            
genated castor oil with E.O.,                                             
and polyethylene glycols and                                              
glycerol ethoxylate                                                       
______________________________________
Example 37 
______________________________________                                    
Clotrimazole         100    mg/tampon                                     
Ethyl lactate        300    mg                                            
Polyglycol molecular 400    mg                                            
weight 1,000                                                              
Polyglycol molecular 1,000  mg                                            
weight 1,500                                                              
Solubiliser as in Example 36                                              
                     200    mg                                            
______________________________________
Example 38 
______________________________________                                    
Bifonazole           100    mg/tampon                                     
Mixture of of mono-, di- and                                              
                     900    mg                                            
triglycerides of saturated                                                
fatty acids of chain length                                               
C.sub.12 -C.sub.18                                                        
Ethyl lactate        400    mg                                            
Hexyl laurate        300    mg                                            
Myristyl lactate     300    mg                                            
______________________________________
Example 39 
______________________________________                                    
Bifonazole           100    mg/tampon                                     
Triglyceride mixture of                                                   
                     800    mg                                            
natural saturated fatty acids                                             
of chain length C.sub.10 -C.sub.18                                        
with the addition of 2% of                                                
non-ionic emulsifier                                                      
Ethyl lactate        400    mg                                            
Benzyl alcohol       100    mg                                            
Myristyl myristate   700    mg                                            
______________________________________
Example 40 
______________________________________                                    
Bifonazole          100    mg/tampon                                      
Polyglycol molecular                                                      
                    400    mg                                             
weight 1,000                                                              
Polyglycol molecular                                                      
                    1,000  mg                                             
weight 1,500                                                              
Ethyl lactate       200    mg                                             
Benzyl alcohol      100    mg                                             
______________________________________
Example 41 
______________________________________                                    
Lombazole            100    mg/tampon                                     
Mixture of mono-, di- and                                                 
                     900    mg                                            
triglycerides of saturated                                                
fatty acids of chain length                                               
C.sub.12 -C.sub.18                                                        
Ethyl lactate        400    mg                                            
Hexyl laurate        300    mg                                            
Myristyl lactate     300    mg                                            
______________________________________
Example 42 
______________________________________                                    
Lombazole             100    mg/tampon                                    
Triglyceride mixture of natural                                           
                      800    mg                                           
saturated fatty acids of chain                                            
length C.sub.10 -C.sub.18 with the                                        
addition of 2% of non-ionic                                               
emulsifier                                                                
Ethyl lactate         300    mg                                           
Benzyl alcohol        100    mg                                           
Myristyl myristate    700    mg                                           
______________________________________
Example 43 
______________________________________                                    
Lombazole           100    mg/tampon                                      
Polyglycol molecular                                                      
                    400    mg                                             
weight 1,000                                                              
Polyglycol molecular                                                      
                    1,100  mg                                             
weight 1,500                                                              
Ethyl lactate       200    mg                                             
Benzyl alcohol      100    mg                                             
______________________________________
Testing the effectiveness of the tampons according to the invention was carried out by sensitivity measurement in the agar diffusion test for Candida albicans and Torulopsis glabrata in accordance with the following method:
In order to measure the release of active compound, 2 each of the different vaginal tampons, impregnated in each case with 100 or 200 mg of the active compounds to be tested, were placed in 10 cm high glass beakers which were filled with Kimmig nutrient agar to a height of 5 cm. Before introducing the tampons, holes of the diameter of the tampons were bored in the centre of the agar dishes using sterile cork borers.
The surfaces of the agar in the dishes were then homogeneously inoculated with suspensions of organisms of C. albicans or T. glabrata. The density of organisms was 104 cells per cm2.
The test dishes thus prepared were incubated at 37° C. for 48 hours in an incubation chamber.
In order to obtain a time scale for release of the active compound from the vaginal tampons, of the 2 tampons employed in each case, one was removed from the culture dish after 3 hours and the other after 6 hours.
After the end of the incubation time, the zones of inhibition which had formed round the test holes due to the release of active compound from the tampons were measured.
The sizes of the zones of inhibition for the individual tampon formulations are compiled in the following table.
              TABLE                                                       
______________________________________                                    
Sizes of zones of inhibition for various vaginal formulations after       
exposure times of 3 and 6 hours for C. albicans and T. glabrata.          
          Size of zone of inhibition in mm .0. after an                   
          exposure time of 3 and 6 hours for                              
Formulation Candida albicans                                              
                          Torulopsis glabrata                             
Examples    3 hours 6 hours   3 hours                                     
                                    6 hours                               
______________________________________                                    
 1          32      32        27    29                                    
 2          37      37        neg.  trace                                 
 3          40      41        34    35                                    
 4          36      36        30    34                                    
 5          43      44        29    33                                    
 6          37      38        29    31                                    
 7          30      35        trace 25                                    
 8          32      33        trace 26                                    
 9          43      43        29    33                                    
10          45      45        30    34                                    
11          40      45        32    35                                    
12          30      39        24    27                                    
13          39      40        25    25                                    
14          35      35        29    31                                    
15          40      40        38    41                                    
16          39      39        35    37                                    
17          40      41        33    35                                    
18          40      40        32    35                                    
19          35      36        27    28                                    
20          39      39        30    29                                    
21          39      39        37    38                                    
23          33      34        28    29                                    
24          34      39        28    28                                    
25          33      34        trace trace                                 
26          32      36        30    30                                    
27          38      40        trace 30                                    
28          34      35        26    27                                    
29          33      36        28    32                                    
30          34      34        29    30                                    
31          32      33        27    28                                    
32          31      32        28    28                                    
33          30      33        trace trace                                 
34          32      37        neg.  trace                                 
35          33      39        29    32                                    
36          34      43        trace trace                                 
37          32      40        neg.  neg.                                  
Known tampons                                                             
            30      34        unclear zones of                            
[see Curr on                  inhibition, growing                         
Therapeutic                   together                                    
Research, Vo. 23,                                                         
No. 6, June 1978,                                                         
661-665]                                                                  
______________________________________

Claims (1)

What is claimed is:
1. A process for the production of vaginal tampons containing pharmaceutical active compounds, comprising preparing a basic material containing active material and formulation auxiliaries by melting the active compound and the formulation auxiliaries and then cooling the resulting melt to 40° C., injecting said basic material into pre-warmed tampons, which are still wrapped in protective foil from the point by means of a pre-warmed injection syringe, and placing the tampons thus impregnated with a point at the bottom in pre-warmed vessels and thus cooling down slowly.
US06/634,941 1982-02-06 1984-07-27 Process for production of vaginal tampons containing pharmaceutical active compound Expired - Fee Related US4582717A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19823204124 DE3204124A1 (en) 1982-02-06 1982-02-06 ANTIMYCOTIC TAMPONS WITH HIGH ACTIVE SUBSTANCE RELEASE
DE3204124 1982-02-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06460083 Division 1983-01-21

Publications (1)

Publication Number Publication Date
US4582717A true US4582717A (en) 1986-04-15

Family

ID=6154988

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/634,941 Expired - Fee Related US4582717A (en) 1982-02-06 1984-07-27 Process for production of vaginal tampons containing pharmaceutical active compound

Country Status (6)

Country Link
US (1) US4582717A (en)
EP (1) EP0085882B1 (en)
JP (1) JPS58138453A (en)
AR (1) AR231923A1 (en)
DE (2) DE3204124A1 (en)
ES (1) ES519558A0 (en)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011850A1 (en) * 1988-06-08 1989-12-14 Fountain Michael W Method for making solvent dilution microcarriers
US5389374A (en) * 1990-10-30 1995-02-14 Mcneil-Ppc, Inc. Prevention of toxin production using absorbent products
US5439685A (en) * 1988-07-11 1995-08-08 S S P L Safe Sex Products Licensing Societe Anonyme Pharmaceutical composition for the prevention of sexually transmitted diseases
US5468236A (en) * 1993-06-09 1995-11-21 Kimberly-Clark Corporation Disposable absorbent product incorporating chemically reactive substance
US5547985A (en) * 1990-10-30 1996-08-20 Mcneil-Ppc, Inc. Additives to feminine products
US5562922A (en) * 1993-03-18 1996-10-08 Cedars-Sinai Medical Center Drug incorporating and release polymeric coating for bioprosthesis
US5641503A (en) * 1989-04-27 1997-06-24 Mcneil-Ppc, Inc. Additives to tampons
US5700239A (en) * 1990-07-24 1997-12-23 Yoon; Inbae Multifunctional devices for use in endoscopic surgical procedures and method therefor
US6071549A (en) * 1992-08-17 2000-06-06 Weyerhaeuser Company Binder treated fibrous webs and products
US6096332A (en) * 1998-06-30 2000-08-01 Mcneil-Ppc, Inc. Adding pharmaceutically active compounds to substrates
US20020188264A1 (en) * 2001-04-11 2002-12-12 Playtex Products, Inc. Fibrous absorbent articles having malodor counteractant
US6558362B1 (en) * 1999-02-03 2003-05-06 Bernard Chaffringeon Disposable device for transferring an active liquid into a body cavity
US6570055B2 (en) 2000-12-21 2003-05-27 Mcneil-Ppc, Inc Apertured polymeric film web with surfactant mixture additive
US20030139709A1 (en) * 2002-01-10 2003-07-24 Gehling Steven Craig Medicated tampon
WO2003063829A1 (en) * 2002-01-10 2003-08-07 Kimberly-Clark Worldwide, Inc. Medicated tampon
US20030153864A1 (en) * 2001-10-16 2003-08-14 Bernard Chaffringeon Disposable device and method for transferring an active liquid into a body cavity
US6670523B1 (en) * 1998-12-21 2003-12-30 Ivf Hartmann Ag Tampon with infection-protection
US6743965B2 (en) 2000-12-21 2004-06-01 Mcneil-Ppc, Inc. Apertured polymeric film web with diol/surfactant additive
US20040197371A1 (en) * 2001-10-02 2004-10-07 Kimberly-Clark Worldwide, Inc. Aromatic compositions as inhibitors of exoprotein production in non-absorbent articles
US20060067990A1 (en) * 2004-09-30 2006-03-30 Kimberly-Clark Worldwide, Inc. Absorbent articles for inhibiting the production of exoproteins
US20060067991A1 (en) * 2004-09-30 2006-03-30 Kimberly-Clark Worldwide, Inc. Non-absorbent articles for inhibiting the production of exoproteins
US7026354B2 (en) 2001-10-02 2006-04-11 Kimberly-Clark Worldwide, Inc. Aromatic compositions for the inhibition of exoprotein production from gram positive bacteria
US7091395B2 (en) * 1999-12-29 2006-08-15 Jean-Bastien Pasquini Antiseptic tampon and method of preparing it
US20060213919A1 (en) * 2005-03-25 2006-09-28 Kimberly-Clark Worldwide, Inc. Protective tube for a medicated tampon
US20060216334A1 (en) * 2005-03-25 2006-09-28 Kimberly-Clark Worldwide, Inc. Methods of manufacturing a medicated tampon assembly
US20060213918A1 (en) * 2005-03-25 2006-09-28 Kimberly-Clark Worldwide, Inc. Dosage cap assembly for an applicator
US20060217652A1 (en) * 2005-03-25 2006-09-28 Kimberly-Clark Worldwide, Inc. Delivery tube assembly for an applicator
US20060218690A1 (en) * 2005-04-01 2006-10-05 James Leslie J Waist-fastening, hip-encompassing apparel with at least one concealed storage compartment
US20060247571A1 (en) * 2005-04-28 2006-11-02 Hayes Rebecca D Dosage form cap for an applicator
US20060264857A1 (en) * 2001-12-21 2006-11-23 Adrian Colbert Absorbent articles with buffer
US20070141118A1 (en) * 2005-12-15 2007-06-21 Damico Joyce A Layered dosage form for a medicated tampon assembly
AU2002336472B2 (en) * 2001-10-02 2007-08-23 Kimberly-Clark Worldwide, Inc. Inhibition of exoprotein production using aromatic compositions
US20070293837A1 (en) * 2006-06-16 2007-12-20 Sokal David C Vaginal drug delivery system and method
US20080154222A1 (en) * 2006-11-24 2008-06-26 Bernard Chaffringeon Catamenial and sanitary tampons
WO2008090440A1 (en) * 2007-01-22 2008-07-31 Carlo Ghisalberti Lipid-based gynaecologic suppository
US20100130951A1 (en) * 2008-11-21 2010-05-27 Pierson Linda M Coating compositions and coated substrates for articles of manufacture used in contact with human body surfaces
US20100136089A1 (en) * 2008-11-21 2010-06-03 Pierson Linda M Location of fatty acid esters on tampons and toxin inhibiting efficacy
US20120071839A1 (en) * 2009-03-23 2012-03-22 Uni-Charm Corporation Tampon

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3393678A (en) * 1966-01-03 1968-07-23 Purex Corp Ltd Tampons and the like
US3481335A (en) * 1967-09-13 1969-12-02 Beutlich Inc Vaginal tampon
US3691271A (en) * 1969-02-04 1972-09-12 Roger Charle Sanitary napkin having homogeneously distributed microcapsules filled with delay releasable bactericidal and fungicidal deodorant
US3724465A (en) * 1971-07-22 1973-04-03 Kimberly Clark Co Tampon coated with insertion aid and method for coating
US3995636A (en) * 1974-01-24 1976-12-07 Murray Jerome L Constrained catamenial device employing adhesive coating
US4340055A (en) * 1980-10-01 1982-07-20 Sneider Vincent R Impregnated tampon and method of fabricating same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3756238A (en) * 1971-03-24 1973-09-04 Kimberly Clark Co Self-lubricating compound for use in hygienic and medical applications, and coated tampons and suppositories made therefrom
FR2245344B1 (en) * 1973-06-26 1977-08-19 Fabre Sa Pierre
CH645022A5 (en) * 1978-12-22 1984-09-14 Luecker P W CONCEPTUAL FOR LOCAL APPLICATION.
US4247552A (en) * 1979-01-11 1981-01-27 Syntex (U.S.A.) Inc. Contraceptive compositions and methods employing 1-substituted imidazole derivatives
EP0024023B2 (en) * 1979-08-11 1992-11-11 Bayer Ag Antimycotic agents with enhanced release of the active ingredients
US4420474A (en) * 1979-10-15 1983-12-13 E. R. Squibb & Sons, Inc. Synergistic antifungal compositions
DE3106635A1 (en) * 1981-02-23 1982-09-09 Bayer Ag ANTIMYCOTIC AGENT WITH HIGH ACTIVE SUBSTANCE RELEASE IN THE FORM OF PEN

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3393678A (en) * 1966-01-03 1968-07-23 Purex Corp Ltd Tampons and the like
US3481335A (en) * 1967-09-13 1969-12-02 Beutlich Inc Vaginal tampon
US3691271A (en) * 1969-02-04 1972-09-12 Roger Charle Sanitary napkin having homogeneously distributed microcapsules filled with delay releasable bactericidal and fungicidal deodorant
US3724465A (en) * 1971-07-22 1973-04-03 Kimberly Clark Co Tampon coated with insertion aid and method for coating
US3995636A (en) * 1974-01-24 1976-12-07 Murray Jerome L Constrained catamenial device employing adhesive coating
US4340055A (en) * 1980-10-01 1982-07-20 Sneider Vincent R Impregnated tampon and method of fabricating same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Current Therapeutic Research, vol. 23, No. 6, Jun., 1978 (5 pages) Miconazole In Vaginal Tampons A New Treatment of Vaginal Candidiasis. *

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011850A1 (en) * 1988-06-08 1989-12-14 Fountain Michael W Method for making solvent dilution microcarriers
US5439685A (en) * 1988-07-11 1995-08-08 S S P L Safe Sex Products Licensing Societe Anonyme Pharmaceutical composition for the prevention of sexually transmitted diseases
US5705182A (en) * 1989-04-27 1998-01-06 Mcneil-Ppc, Inc. Additives to tampons
US5641503A (en) * 1989-04-27 1997-06-24 Mcneil-Ppc, Inc. Additives to tampons
US5679369A (en) * 1989-04-27 1997-10-21 Mcneil-Ppc, Inc. Additives to tampons
US5700239A (en) * 1990-07-24 1997-12-23 Yoon; Inbae Multifunctional devices for use in endoscopic surgical procedures and method therefor
US5389374A (en) * 1990-10-30 1995-02-14 Mcneil-Ppc, Inc. Prevention of toxin production using absorbent products
US5547985A (en) * 1990-10-30 1996-08-20 Mcneil-Ppc, Inc. Additives to feminine products
US5753252A (en) * 1990-10-30 1998-05-19 Mcneil-Ppc, Inc. Prevention of toxin production using absorbent products
US6071549A (en) * 1992-08-17 2000-06-06 Weyerhaeuser Company Binder treated fibrous webs and products
US5900246A (en) * 1993-03-18 1999-05-04 Cedars-Sinai Medical Center Drug incorporating and releasing polymeric coating for bioprosthesis
US5562922A (en) * 1993-03-18 1996-10-08 Cedars-Sinai Medical Center Drug incorporating and release polymeric coating for bioprosthesis
US5468236A (en) * 1993-06-09 1995-11-21 Kimberly-Clark Corporation Disposable absorbent product incorporating chemically reactive substance
US7341737B2 (en) 1997-06-11 2008-03-11 Kimberly-Clark Worldwide, Inc. Medicated tampon
US6096332A (en) * 1998-06-30 2000-08-01 Mcneil-Ppc, Inc. Adding pharmaceutically active compounds to substrates
US6316019B1 (en) 1998-06-30 2001-11-13 Mcneil-Ppc, Inc. Process for adding pharmaceutically active compounds to substrates
US6670523B1 (en) * 1998-12-21 2003-12-30 Ivf Hartmann Ag Tampon with infection-protection
US6558362B1 (en) * 1999-02-03 2003-05-06 Bernard Chaffringeon Disposable device for transferring an active liquid into a body cavity
US20030191439A1 (en) * 1999-02-03 2003-10-09 Bernard Chaffringeon Disposable device for transferring an active liquid into a body cavity
US7091395B2 (en) * 1999-12-29 2006-08-15 Jean-Bastien Pasquini Antiseptic tampon and method of preparing it
US6570055B2 (en) 2000-12-21 2003-05-27 Mcneil-Ppc, Inc Apertured polymeric film web with surfactant mixture additive
US6743965B2 (en) 2000-12-21 2004-06-01 Mcneil-Ppc, Inc. Apertured polymeric film web with diol/surfactant additive
US20020188264A1 (en) * 2001-04-11 2002-12-12 Playtex Products, Inc. Fibrous absorbent articles having malodor counteractant
US8093446B2 (en) * 2001-04-11 2012-01-10 Playtex Products, Inc. Fibrous absorbent articles having malodor counteractant
US20060135616A1 (en) * 2001-10-02 2006-06-22 Kimberly-Clark Worldwide, Inc. Aromatic compositions for the inhibition of exoprotein production from gram positive bacteria
US7258867B2 (en) 2001-10-02 2007-08-21 Kimberly-Clark Worldwide, Inc. Aromatic compositions as inhibitors of exoprotein production in non-absorbent articles
US7022333B2 (en) * 2001-10-02 2006-04-04 Kimberly-Clark Worldwide, Inc. Inhibition of exoprotein production in non-absorbent articles uisng aromatic compositions
US7026354B2 (en) 2001-10-02 2006-04-11 Kimberly-Clark Worldwide, Inc. Aromatic compositions for the inhibition of exoprotein production from gram positive bacteria
US20040197371A1 (en) * 2001-10-02 2004-10-07 Kimberly-Clark Worldwide, Inc. Aromatic compositions as inhibitors of exoprotein production in non-absorbent articles
AU2002336472B2 (en) * 2001-10-02 2007-08-23 Kimberly-Clark Worldwide, Inc. Inhibition of exoprotein production using aromatic compositions
US20030153864A1 (en) * 2001-10-16 2003-08-14 Bernard Chaffringeon Disposable device and method for transferring an active liquid into a body cavity
US20070255232A1 (en) * 2001-10-16 2007-11-01 Bernard Chaffringeon Disposable device and method for transferring an active liquid into a body cavity
US20060264857A1 (en) * 2001-12-21 2006-11-23 Adrian Colbert Absorbent articles with buffer
US20030139709A1 (en) * 2002-01-10 2003-07-24 Gehling Steven Craig Medicated tampon
US7344732B2 (en) 2002-01-10 2008-03-18 Kimberly-Clark Worldwide, Inc. Medicated tampon
WO2003063829A1 (en) * 2002-01-10 2003-08-07 Kimberly-Clark Worldwide, Inc. Medicated tampon
AU2003219653B2 (en) * 2002-01-10 2007-11-29 Kimberly-Clark Worldwide, Inc. Medicated tampon
KR100978981B1 (en) * 2002-01-10 2010-08-30 킴벌리-클라크 월드와이드, 인크. Medicated tampon
US20060067990A1 (en) * 2004-09-30 2006-03-30 Kimberly-Clark Worldwide, Inc. Absorbent articles for inhibiting the production of exoproteins
US20060067991A1 (en) * 2004-09-30 2006-03-30 Kimberly-Clark Worldwide, Inc. Non-absorbent articles for inhibiting the production of exoproteins
US7744556B2 (en) 2005-03-25 2010-06-29 Kimberly-Clark Worldwide, Inc. Delivery tube assembly for an applicator
US20060213919A1 (en) * 2005-03-25 2006-09-28 Kimberly-Clark Worldwide, Inc. Protective tube for a medicated tampon
US7919453B2 (en) 2005-03-25 2011-04-05 Kimberly-Clark Worldwide, Inc. Dosage cap assembly for an applicator
US20060216334A1 (en) * 2005-03-25 2006-09-28 Kimberly-Clark Worldwide, Inc. Methods of manufacturing a medicated tampon assembly
US7993667B2 (en) 2005-03-25 2011-08-09 Kimberly-Clark Worldwide, Inc. Methods of manufacturing a medicated tampon assembly
US20060217652A1 (en) * 2005-03-25 2006-09-28 Kimberly-Clark Worldwide, Inc. Delivery tube assembly for an applicator
US20060213918A1 (en) * 2005-03-25 2006-09-28 Kimberly-Clark Worldwide, Inc. Dosage cap assembly for an applicator
US8388996B2 (en) 2005-03-25 2013-03-05 Kimberly-Clark Worldwide, Inc. Methods of manufacturing a medicated tampon assembly
US7527614B2 (en) 2005-03-25 2009-05-05 Kimberly-Clark Worldwide, Inc. Protective tube for a medicated tampon
US20060218690A1 (en) * 2005-04-01 2006-10-05 James Leslie J Waist-fastening, hip-encompassing apparel with at least one concealed storage compartment
US7708726B2 (en) 2005-04-28 2010-05-04 Kimberly-Clark Worldwide, Inc. Dosage form cap for an applicator
US20060247571A1 (en) * 2005-04-28 2006-11-02 Hayes Rebecca D Dosage form cap for an applicator
US20070141118A1 (en) * 2005-12-15 2007-06-21 Damico Joyce A Layered dosage form for a medicated tampon assembly
US8137327B2 (en) 2006-06-16 2012-03-20 Family Health International Vaginal drug delivery system and method
US20070293837A1 (en) * 2006-06-16 2007-12-20 Sokal David C Vaginal drug delivery system and method
US20080154222A1 (en) * 2006-11-24 2008-06-26 Bernard Chaffringeon Catamenial and sanitary tampons
EP2094217B1 (en) 2006-11-24 2016-03-30 Intigena (Schweiz)AG Catamenial and sanitary tampons
WO2008090440A1 (en) * 2007-01-22 2008-07-31 Carlo Ghisalberti Lipid-based gynaecologic suppository
US20100136089A1 (en) * 2008-11-21 2010-06-03 Pierson Linda M Location of fatty acid esters on tampons and toxin inhibiting efficacy
US20100130951A1 (en) * 2008-11-21 2010-05-27 Pierson Linda M Coating compositions and coated substrates for articles of manufacture used in contact with human body surfaces
US8237011B2 (en) 2008-11-21 2012-08-07 McNeil—PPC, Inc. Coating compositions and coated substrates for articles of manufacture used in contact with human body surfaces
US8425480B2 (en) 2008-11-21 2013-04-23 Mcneil-Ppc, Inc. Location of fatty acid esters on tampons and toxin inhibiting efficacy
US20120071839A1 (en) * 2009-03-23 2012-03-22 Uni-Charm Corporation Tampon

Also Published As

Publication number Publication date
EP0085882A2 (en) 1983-08-17
ES8406203A1 (en) 1984-07-01
DE3204124A1 (en) 1983-08-18
ES519558A0 (en) 1984-07-01
DE3363118D1 (en) 1986-05-28
AR231923A1 (en) 1985-04-30
EP0085882B1 (en) 1986-04-23
JPS58138453A (en) 1983-08-17
EP0085882A3 (en) 1983-11-16

Similar Documents

Publication Publication Date Title
US4582717A (en) Process for production of vaginal tampons containing pharmaceutical active compound
US4680172A (en) Devices and methods for treating memory impairment
US5059593A (en) Pour-on formulations which are active against ticks
EA002825B1 (en) 2-methyl-thieno-benzodiazepine formulation
US4765985A (en) Devices and methods for treating memory impairment
US4096262A (en) Pour-on anthelmintics
CA1169770A (en) Antimycotic agent, in the form of sticks, with a high release of active compound
KR890001521A (en) Sustained Release New Pharmaceutical Formulations
EP0055029B1 (en) Preparations for the treatment of dermatoses
EP0179808A1 (en) Pharmaceutical composition suitable for treatment or prophylaxis of cardiac disorders.
EA002580B1 (en) 2-methyl-thieno-benzodiazepine formulation
JPS62108812A (en) Nitroglycerin percutaneous administration product
JPS60239421A (en) Local blended drug for accelerating wound granulation and epithelial formation and manufacture
CN115607528B (en) Application of D-arabitol in lipid-lowering and liver-protecting
CS268651B2 (en) Method of pharmaceutical production for rectal dosage
KR910004480B1 (en) Process for preparing antimycotic agents
US5489615A (en) Pharmaceutical ointment being free from skin irritative action and a process for the preparation thereof
Olansky et al. Growth of heterologous human tumors from aging individuals in hamster cheek pouches
JPH0234924B2 (en) IMIDAZOORUJUDOTAIOFUKUMUHININNYUYONASOSEIBUTSU
NZ207235A (en) Antifungal pharmaceutical compositions containing imidazole derivatives
WO2012041966A1 (en) Ovule for vaginal administration of arasertaconazole
CN117898305A (en) Preparation method and application of bifenthrin and chlorantraniliprole termite control composition
Zhu et al. Clinical use of homograft stored by vitrification
SE8401748L (en) ANTIMYCOTIC MEDICINE IN THE FORM OF CREAM WITH HIGH-GRADUATE RELEASE OF ACTIVE SUBSTANCE
EP0339176A1 (en) Suppository containing a non-steroidal anti-inflammatory medicament

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19940628

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362